citalopram has been researched along with Irritable Bowel Syndrome in 14 studies
Citalopram: A furancarbonitrile that is one of the serotonin uptake inhibitors used as an antidepressant. The drug is also effective in reducing ethanol uptake in alcoholics and is used in depressed patients who also suffer from TARDIVE DYSKINESIA in preference to tricyclic antidepressants, which aggravate dyskinesia.
citalopram : A racemate comprising equimolar amounts of (R)-citalopram and its enantiomer, escitalopram. It is used as an antidepressant, although only escitalopram is active.
1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile : A nitrile that is 1,3-dihydro-2-benzofuran-5-carbonitrile in which one of the hydrogens at position 1 is replaced by a p-fluorophenyl group, while the other is replaced by a 3-(dimethylamino)propyl group.
Irritable Bowel Syndrome: A disorder with chronic or recurrent colonic symptoms without a clearcut etiology. This condition is characterized by chronic or recurrent ABDOMINAL PAIN, bloating, MUCUS in FECES, and an erratic disturbance of DEFECATION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Momentary ecological assessment indicated alleviated abdominal pain in escitalopram treatment of irritable bowel syndrome (IBS) with comorbid panic disorder." | 9.41 | Symptom-network dynamics in irritable bowel syndrome with comorbid panic disorder using electronic momentary assessment: A randomized controlled trial of escitalopram vs. placebo. ( Drukker, M; Kreiter, D; Kruimel, JW; Leue, C; Masclee, AAM; Mujagic, Z; Rutten, BPF; van Os, J; Vork, L, 2021) |
| " This study evaluated differences in change in abdominal pain between real-time (ie, ESM) and retrospective (ie, Gastrointestinal Symptom Rating Scale [GSRS] and an end-of-day symptom diary) measurements, using data of an RCT on escitalopram vs placebo in patients with IBS and comorbid panic disorder." | 9.30 | The Experience Sampling Method-Evaluation of treatment effect of escitalopram in IBS with comorbid panic disorder. ( Conchillo, JM; Drukker, M; Hesselink, MAM; Keszthelyi, D; Kruimel, JW; Leue, C; Masclee, AAM; Mujagic, Z; van Os, J; Vork, L, 2019) |
| "After three and six weeks of treatment, citalopram significantly improved abdominal pain, bloating, impact of symptoms on daily life, and overall well being compared with placebo." | 9.12 | A controlled crossover study of the selective serotonin reuptake inhibitor citalopram in irritable bowel syndrome. ( Broekaert, D; Fischler, B; Gevers, AM; Janssens, J; Tack, J; Van Oudenhove, L, 2006) |
| "Citalopram was not superior to placebo in treating non-depressed IBS patients." | 6.75 | Citalopram provides little or no benefit in nondepressed patients with irritable bowel syndrome. ( Bacchetti, P; Chung, E; Grimes, B; Jin, C; Ladabaum, U; Levin, TR; Pepin, CJ; Sharabidze, A; Zhao, WK, 2010) |
| "Citalopram was not superior to placebo." | 6.73 | Antidepressant therapy (imipramine and citalopram) for irritable bowel syndrome: a double-blind, randomized, placebo-controlled trial. ( Boyce, P; Huskic, S; Jones, M; Kellow, JE; Talley, NJ; Tennant, C, 2008) |
| "Momentary ecological assessment indicated alleviated abdominal pain in escitalopram treatment of irritable bowel syndrome (IBS) with comorbid panic disorder." | 5.41 | Symptom-network dynamics in irritable bowel syndrome with comorbid panic disorder using electronic momentary assessment: A randomized controlled trial of escitalopram vs. placebo. ( Drukker, M; Kreiter, D; Kruimel, JW; Leue, C; Masclee, AAM; Mujagic, Z; Rutten, BPF; van Os, J; Vork, L, 2021) |
| " This study evaluated differences in change in abdominal pain between real-time (ie, ESM) and retrospective (ie, Gastrointestinal Symptom Rating Scale [GSRS] and an end-of-day symptom diary) measurements, using data of an RCT on escitalopram vs placebo in patients with IBS and comorbid panic disorder." | 5.30 | The Experience Sampling Method-Evaluation of treatment effect of escitalopram in IBS with comorbid panic disorder. ( Conchillo, JM; Drukker, M; Hesselink, MAM; Keszthelyi, D; Kruimel, JW; Leue, C; Masclee, AAM; Mujagic, Z; van Os, J; Vork, L, 2019) |
| "The aims of the study were to evaluate the effect of the administration of ATD and citalopram on rectal motor function in diarrhea-predominant IBS (d-IBS) patients and controls using a barostat procedure." | 5.16 | The effect of acute serotonergic modulation on rectal motor function in diarrhea-predominant irritable bowel syndrome and healthy controls. ( Kilkens, TO; van Nieuwenhoven, MA, 2012) |
| "After three and six weeks of treatment, citalopram significantly improved abdominal pain, bloating, impact of symptoms on daily life, and overall well being compared with placebo." | 5.12 | A controlled crossover study of the selective serotonin reuptake inhibitor citalopram in irritable bowel syndrome. ( Broekaert, D; Fischler, B; Gevers, AM; Janssens, J; Tack, J; Van Oudenhove, L, 2006) |
| "To assess the effects of an acutely increased serotonergic activity, using a 20 mg intravenous citalopram challenge test on visceral perception, affective memory performance, mood and neuroendocrine responses, respectively, in diarrhoea-predominant irritable bowel syndrome patients and controls." | 5.11 | The effects of an acute serotonergic challenge on brain-gut responses in irritable bowel syndrome patients and controls. ( Brummer, RJ; Fekkes, D; Honig, A; Kilkens, TO, 2005) |
| "Citalopram was not superior to placebo in treating non-depressed IBS patients." | 2.75 | Citalopram provides little or no benefit in nondepressed patients with irritable bowel syndrome. ( Bacchetti, P; Chung, E; Grimes, B; Jin, C; Ladabaum, U; Levin, TR; Pepin, CJ; Sharabidze, A; Zhao, WK, 2010) |
| "Citalopram was not superior to placebo." | 2.73 | Antidepressant therapy (imipramine and citalopram) for irritable bowel syndrome: a double-blind, randomized, placebo-controlled trial. ( Boyce, P; Huskic, S; Jones, M; Kellow, JE; Talley, NJ; Tennant, C, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (42.86) | 29.6817 |
| 2010's | 6 (42.86) | 24.3611 |
| 2020's | 2 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Kreiter, D | 1 |
| Drukker, M | 2 |
| Mujagic, Z | 2 |
| Vork, L | 2 |
| Rutten, BPF | 1 |
| van Os, J | 2 |
| Masclee, AAM | 2 |
| Kruimel, JW | 2 |
| Leue, C | 2 |
| de Bruijn, CMA | 1 |
| Rexwinkel, R | 1 |
| Gordon, M | 1 |
| Benninga, M | 1 |
| Tabbers, MM | 1 |
| Cooper, TE | 1 |
| Heathcote, LC | 1 |
| Clinch, J | 1 |
| Gold, JI | 1 |
| Howard, R | 1 |
| Lord, SM | 1 |
| Schechter, N | 1 |
| Wood, C | 1 |
| Wiffen, PJ | 1 |
| Keszthelyi, D | 1 |
| Conchillo, JM | 1 |
| Hesselink, MAM | 1 |
| Bundeff, AW | 1 |
| Woodis, CB | 1 |
| Schmidt, C | 1 |
| Ladabaum, U | 1 |
| Sharabidze, A | 1 |
| Levin, TR | 1 |
| Zhao, WK | 1 |
| Chung, E | 1 |
| Bacchetti, P | 1 |
| Jin, C | 1 |
| Grimes, B | 1 |
| Pepin, CJ | 1 |
| van Nieuwenhoven, MA | 1 |
| Kilkens, TO | 2 |
| Honig, A | 1 |
| Fekkes, D | 1 |
| Brummer, RJ | 1 |
| Tack, J | 1 |
| Broekaert, D | 1 |
| Fischler, B | 1 |
| Van Oudenhove, L | 1 |
| Gevers, AM | 1 |
| Janssens, J | 1 |
| Creed, F | 1 |
| Castle, M | 1 |
| Libby, GW | 1 |
| van Kerkhoven, LA | 1 |
| Laheij, RJ | 1 |
| Jansen, JB | 1 |
| Talley, NJ | 1 |
| Kellow, JE | 1 |
| Boyce, P | 1 |
| Tennant, C | 1 |
| Huskic, S | 1 |
| Jones, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Kynurenine Pathway Metabolites as Novel Translational Biological Markers of Irritable Bowel Syndrome: Relationship to Gastrointestinal Function, Cognition and Co-morbid Depression[NCT01304355] | 85 participants (Anticipated) | Observational | 2011-01-31 | Recruiting | |||
| A Double-Blind, Randomized, Placebo-Controlled Multicenter Study to Assess the Safety and Efficacy of AST-120 in Patients With Non-Constipating Irritable Bowel Syndrome[NCT00583128] | Phase 2 | 117 participants (Actual) | Interventional | 2007-08-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for citalopram and Irritable Bowel Syndrome
| Article | Year |
|---|---|
Antidepressants for functional abdominal pain disorders in children and adolescents.
Topics: Abdominal Pain; Adolescent; Amitriptyline; Antidepressive Agents, Second-Generation; Antidepressive | 2021 |
Antidepressants for chronic non-cancer pain in children and adolescents.
Topics: Abdominal Pain; Adolescent; Amines; Amitriptyline; Analgesics; Antidepressive Agents; Child; Chronic | 2017 |
Selective serotonin reuptake inhibitors for the treatment of irritable bowel syndrome.
Topics: Citalopram; Fluoxetine; Humans; Irritable Bowel Syndrome; Paroxetine; Randomized Controlled Trials a | 2014 |
How do SSRIs help patients with irritable bowel syndrome?
Topics: Antidepressive Agents, Second-Generation; Citalopram; Humans; Irritable Bowel Syndrome; Selective Se | 2006 |
7 trials available for citalopram and Irritable Bowel Syndrome
| Article | Year |
|---|---|
Symptom-network dynamics in irritable bowel syndrome with comorbid panic disorder using electronic momentary assessment: A randomized controlled trial of escitalopram vs. placebo.
Topics: Adolescent; Adult; Aged; Citalopram; Comorbidity; Double-Blind Method; Ecological Momentary Assessme | 2021 |
The Experience Sampling Method-Evaluation of treatment effect of escitalopram in IBS with comorbid panic disorder.
Topics: Adult; Citalopram; Comorbidity; Computers, Handheld; Double-Blind Method; Female; Humans; Irritable | 2019 |
Citalopram provides little or no benefit in nondepressed patients with irritable bowel syndrome.
Topics: Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Citalopram; Depression; Double-Bl | 2010 |
The effect of acute serotonergic modulation on rectal motor function in diarrhea-predominant irritable bowel syndrome and healthy controls.
Topics: Adult; Arousal; Brain; Citalopram; Cross-Over Studies; Diarrhea; Double-Blind Method; Emotions; Fema | 2012 |
The effects of an acute serotonergic challenge on brain-gut responses in irritable bowel syndrome patients and controls.
Topics: Adolescent; Adrenocorticotropic Hormone; Adult; Affect; Brain; Citalopram; Cross-Over Studies; Doubl | 2005 |
A controlled crossover study of the selective serotonin reuptake inhibitor citalopram in irritable bowel syndrome.
Topics: Abdominal Pain; Adult; Aged; Antidepressive Agents, Second-Generation; Anxiety; Citalopram; Cross-Ov | 2006 |
Antidepressant therapy (imipramine and citalopram) for irritable bowel syndrome: a double-blind, randomized, placebo-controlled trial.
Topics: Adult; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Citalopram; Doubl | 2008 |
3 other studies available for citalopram and Irritable Bowel Syndrome
| Article | Year |
|---|---|
Mental health: thinking from the gut.
Topics: Animals; Anxiety; Autistic Disorder; Bacteroides fragilis; Bifidobacterium; Blood-Brain Barrier; Bra | 2015 |
Further evidence supporting a psychological component to irritable bowel syndrome.
Topics: Antidepressive Agents, Second-Generation; Anxiety; Citalopram; Humans; Irritable Bowel Syndrome; Som | 2007 |
The role of the selective serotonin reuptake inhibitor citalopram in irritable bowel syndrome.
Topics: Antidepressive Agents, Second-Generation; Citalopram; Humans; Irritable Bowel Syndrome; Research Des | 2007 |